Long-Term Safety and Efficacy Data Available on Vabysmo for Diabetic Macular Edema
https://unsplash.com/photos/In4XVKhYaiI

Long-Term Safety and Efficacy Data Available on Vabysmo for Diabetic Macular Edema

Since its development and approval, Vabysmo has been a game-changer in the ophthalmologic space. The injectable VEGF and Ang-2 inhibitor treats diabetic macular edema (DME), macular edema with retinal vein…

Continue Reading Long-Term Safety and Efficacy Data Available on Vabysmo for Diabetic Macular Edema
Phase 2 Obesity Clinical Trial from Palatin Set to Begin
source: shutterstock.com

Phase 2 Obesity Clinical Trial from Palatin Set to Begin

According to a story from drugs.com, the biopharmaceutical company Palatin Technologies, Inc., which is specializing in the development of therapies that interact with the melanocortin receptor system, recently announced the…

Continue Reading Phase 2 Obesity Clinical Trial from Palatin Set to Begin
SLEEP 2024: Two Studies Explore Link Between Narcolepsy and Cardiovascular Disease Risk
https://pixabay.com/en/man-sleeping-man-nap-napping-male-1245993/

SLEEP 2024: Two Studies Explore Link Between Narcolepsy and Cardiovascular Disease Risk

The SLEEP 2024 Annual Meeting took place this year from June 1 to June 5 in Houston, TX. During the course of this premier sleep conference, stakeholders across the sleep…

Continue Reading SLEEP 2024: Two Studies Explore Link Between Narcolepsy and Cardiovascular Disease Risk
Rare Community Profiles: The Third Elephant on the Ramp to the Ark: How Carl’s Advocacy Affected His iMCD Journey
Fotocitizen / Pixabay

Rare Community Profiles: The Third Elephant on the Ramp to the Ark: How Carl’s Advocacy Affected His iMCD Journey

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: The Third Elephant on the Ramp to the Ark: How Carl’s Advocacy Affected His iMCD Journey
Long COVID: What Have We Learned?
source: shutterstock.com

Long COVID: What Have We Learned?

Individuals who appear to have Long COVID may exhibit a variety of symptoms lasting weeks or even years. The latest estimates are that about 10-20% of people infected with SARS-CoV-2…

Continue Reading Long COVID: What Have We Learned?
Rare Community Profiles: Superhero Liam Battles KAND with the Help of Shriners Children’s
Fotocitizen / Pixabay

Rare Community Profiles: Superhero Liam Battles KAND with the Help of Shriners Children’s

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: Superhero Liam Battles KAND with the Help of Shriners Children’s
Neurofibromatosis Type 1: A Mother’s Struggle Living with Thousands of Tumors
source: shutterstock.com

Neurofibromatosis Type 1: A Mother’s Struggle Living with Thousands of Tumors

According to a story from StokeonTrentLive, 34-year-old mother Rachel Potter is living with thousands of tumors thanks to a rare genetic disorder called neurofibromatosis type 1 (NF1). Though they aren't…

Continue Reading Neurofibromatosis Type 1: A Mother’s Struggle Living with Thousands of Tumors
STUDY: 33% of Adults with Severe Autoimmune Hemolytic Anemia Responded Well to Add-On IVIG
qimono / Pixabay

STUDY: 33% of Adults with Severe Autoimmune Hemolytic Anemia Responded Well to Add-On IVIG

Prednisone, oral steroids, intravenous hydrocortisone, and even blood transfusions are used to treat autoimmune hemolytic anemia (AIHA). AIHA comprises of warm AIHA, mixed AIHA, or cold agglutinin disease (CAD). Some…

Continue Reading STUDY: 33% of Adults with Severe Autoimmune Hemolytic Anemia Responded Well to Add-On IVIG
New Podcast Episode: Epilepsy and Unmet Need, feat. The LGS Foundation and Ovid Therapeutics
source: shutterstock.com

New Podcast Episode: Epilepsy and Unmet Need, feat. The LGS Foundation and Ovid Therapeutics

Patient Worthy's award-winning podcast "Wait, How Do You Spell That? A Rare Disease Podcast" is back with a new episode. This week, Colby is sitting down with Dr. Tracy Dixon-Salazar,…

Continue Reading New Podcast Episode: Epilepsy and Unmet Need, feat. The LGS Foundation and Ovid Therapeutics
Japanese Scientists Reversed Signs of Alzheimer’s by Restoring Synapse Function in Mouse Model
source: shutterstock.com

Japanese Scientists Reversed Signs of Alzheimer’s by Restoring Synapse Function in Mouse Model

A team of scientists from Japan appear to have pioneered a method for reversing synapse damage in an Alzheimer's disease mouse model. Although encouraging, the theory must be tested in…

Continue Reading Japanese Scientists Reversed Signs of Alzheimer’s by Restoring Synapse Function in Mouse Model
This Drug Could Prevent PAH in People with Scleroderma
source: shutterstock.com

This Drug Could Prevent PAH in People with Scleroderma

According to a story from Scleroderma News, findings from the recent Phase 2 EDITA clinical trial suggested that ambrisentan (marketed as Letairis), which is approved to treat pulmonary arterial hypertension…

Continue Reading This Drug Could Prevent PAH in People with Scleroderma
Rare Community Profiles: The Monster Inside: How a Boundary-Breaking Treatment Helped Sean in His Battle with von Hippel-Lindau Syndrome
source: pixabay.com

Rare Community Profiles: The Monster Inside: How a Boundary-Breaking Treatment Helped Sean in His Battle with von Hippel-Lindau Syndrome

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: The Monster Inside: How a Boundary-Breaking Treatment Helped Sean in His Battle with von Hippel-Lindau Syndrome
FDA’s Panel of Experts Vote 11-0 in Favor of Donanemab to Treat Alzheimer’s Disease
source: shutterstock.com

FDA’s Panel of Experts Vote 11-0 in Favor of Donanemab to Treat Alzheimer’s Disease

The idiom ‘third time’s a charm’ may have some significance in this instance. The panel that advises the FDA just voted unanimously in favor of Eli Lilly’s experimental drug, donanemab.…

Continue Reading FDA’s Panel of Experts Vote 11-0 in Favor of Donanemab to Treat Alzheimer’s Disease